For Quick Alerts
For Daily Alerts

Biocon Hits 52-Week High After FDA Nod for Biosimilar Cancer Drug


Biocon Ltd and Mylan N.V collaboration received an approval for their biosimilar pegfilgrastim from the American regulator FDA (US Food and Drug Administration) to sell in the US market.

Biocon Hits 52-Week High After FDA Nod for Biosimilar Cancer Drug

"Fulphila is expected to be the first biosimilar pegfilgrastim available in the U.S. to help patients with nonmyeloid cancers reduce the risk of infection following myelosuppressive chemotherapy. Fulphila is the second FDA-approved biosimilar through the Mylan-Biocon collaboration, further demonstrating the companies' leadership and commitment to expanding patient access to critical biologic medicines," said Biocon in a press release.

The company also announced the news through its Twitter handle.

Biocon shares reacted to the news by rising as much as 6.4 percent in early morning trade today to a new record high of Rs 696.60.

Last year, the collaboration got FDA approval for their breast cancer drug Trastuzumab. Fulphila is expected to be launched in the coming weeks.

Biosimilars are highly similar to already approved and sold biological medical product. The brand Neulasta already sells pegfilgrastim in the US.

Read more about: biocon fda
Story first published: Tuesday, June 5, 2018, 14:05 [IST]
Company Search
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more